Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PPH Clear all
Withdrawn Phase 4 Interventional

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

NCT00625469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Jul 21, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Jul 21, 2026, 7:05 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Jul 21, 2026, 7:05 AM EDT
Withdrawn Not applicable Interventional

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

NCT01645826
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Interventions
Diltiazem Hydrochloride, Sugar Pill
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jul 21, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage

NCT06452355
View directory record Official record
Conditions
Postpartum Hemorrhage, Immediate Postpartum Hemorrhage, Hemorrhage, Postpartum
Interventions
KOKO Device
Device
Lead sponsor
KOKO Medical Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Newark, Delaware • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 21, 2026, 7:05 AM EDT
Withdrawn Phase 4 Interventional

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

NCT03309592
View directory record Official record
Conditions
Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
Interventions
Ambrisentan Pill, Tadalafil Pill
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jul 21, 2026, 7:05 AM EDT
Recruiting Not applicable Interventional

Mobile Health Intervention to Improve Exercise in Pediatric PH

NCT06549452
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
mHealth Intervention, Usual Care
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT00086463
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
Interventions
Iloprost or placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

DAISY Uterine Drain Device Evaluation

NCT06219538
View directory record Official record
Conditions
Cesarean Section Complications, Post Partum Hemorrhage, Uterine Atony With Hemorrhage, Uterine Bleeding
Interventions
DAISY Uterine Drain
Device
Lead sponsor
Raydiant Oximetry, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 7:05 AM EDT
Terminated No phase listed Observational

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

NCT00722254
View directory record Official record
Conditions
Primary Myelofibrosis, Primary Pulmonary Hypertension, Secondary Myelofibrosis, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jul 21, 2026, 7:05 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients

NCT01913457
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ultrasound Doppler
Radiation
Lead sponsor
Echosense Ltd.
Industry
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Jul 21, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 80 Years
Enrollment
150 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 21, 2026, 7:05 AM EDT
Not listed Not applicable Interventional

Right Ventricular Pacing in Pulmonary Arterial Hypertension

NCT04194632
View directory record Official record
Conditions
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Interventions
Temporary right ventricular pacing
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Phase 2 Interventional

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

NCT00046319
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BSF 208075
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2009 · Synced Jul 21, 2026, 7:05 AM EDT
Completed No phase listed Observational

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension

NCT00091546
View directory record Official record
Conditions
Lung Diseases, Hypertension, Pulmonary
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 100 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Jul 21, 2026, 7:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension

NCT04745000
View directory record Official record
Conditions
Hypertension;Pulmonary;Primary
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 6 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Endothelin in Pulmonary Hypertension

NCT00759408
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
BQ-123
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 21, 2026, 7:05 AM EDT
Completed No phase listed Observational

Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)

NCT02981758
View directory record Official record
Conditions
Post-partum Hemorrhage (PPH)
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 21, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

NCT03617458
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
Metformin, Placebo, mHealth Intervention, Usual Care
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 21, 2026, 7:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hormonal, Metabolic, and Signaling Interactions in PAH

NCT01884051
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
1,899 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 21, 2026, 7:05 AM EDT
Withdrawn No phase listed Observational

Pharmacogenomics in Pulmonary Arterial Hypertension

NCT00593905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions
Sitaxsentan, Bosentan, Ambrisentan
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 21, 2026, 7:05 AM EDT